Clinical Trial Update: Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy [Phase 2]

View source ↗

Summary

This clinical trial update describes an open-label extension study of Wave Life Sciences' WVE-N531 for Duchenne Muscular Dystrophy in Phase 2, with ongoing enro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• WVE-N531

Snippet

Sponsor: Wave Life Sciences Ltd. | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: ENROLLING_BY_INVITATION